- Home
- MNPR vs ATOM Comparison
MNPR vs ATOM Comparison
Compare MNPR & ATOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ATOM
- Stock Information
- Founded
- MNPR 2014
- ATOM 2001
- Country
- MNPR United States
- ATOM United States
- Employees
- MNPR N/A
- ATOM N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ATOM Semiconductors
- Sector
- MNPR Health Care
- ATOM Technology
- Exchange
- MNPR Nasdaq
- ATOM Nasdaq
- Market Cap
- MNPR 244.1M
- ATOM 248.9M
- IPO Year
- MNPR 2019
- ATOM 2016
- Fundamental
- Price
- MNPR $40.33
- ATOM $4.14
- Analyst Decision
- MNPR Strong Buy
- ATOM Strong Buy
- Analyst Count
- MNPR 5
- ATOM 1
- Target Price
- MNPR $49.60
- ATOM $7.00
- AVG Volume (30 Days)
- MNPR 30.6K
- ATOM 482.5K
- Earning Date
- MNPR 05-08-2025
- ATOM 04-24-2025
- Dividend Yield
- MNPR N/A
- ATOM N/A
- EPS Growth
- MNPR N/A
- ATOM N/A
- EPS
- MNPR N/A
- ATOM N/A
- Revenue
- MNPR N/A
- ATOM $135,000.00
- Revenue This Year
- MNPR $34.06
- ATOM $580.00
- Revenue Next Year
- MNPR N/A
- ATOM N/A
- P/E Ratio
- MNPR N/A
- ATOM N/A
- Revenue Growth
- MNPR N/A
- ATOM N/A
- 52 Week Low
- MNPR $1.72
- ATOM $2.31
- 52 Week High
- MNPR $54.30
- ATOM $17.55
- Technical
- Relative Strength Index (RSI)
- MNPR 56.65
- ATOM 32.62
- Support Level
- MNPR $36.80
- ATOM $4.71
- Resistance Level
- MNPR $43.00
- ATOM $6.08
- Average True Range (ATR)
- MNPR 5.32
- ATOM 0.39
- MACD
- MNPR 0.94
- ATOM -0.05
- Stochastic Oscillator
- MNPR 63.41
- ATOM 5.53
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ATOM Atomera Incorporated
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, FinFET technology, logic and processors, and SRAM.